ELEVOSTEO is a recombinant form of Teriparatide. It is also known as ‘Recombinant Para Thyroid Hormone’. ELEVOSTEO is administered by injection once a day in the thigh or abdomen in ‘Sub-Cutaneous’ (S.C) form. The recommended dose of ELEVOSTEO is 20 μg (S.C) per day.

Teriparatide is a portion of Human Parathyroid Hormone(PTH), amino acid sequence 1 through 34, of the complete molecule (containing 84 amino acids). In the human body, PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. PTH increases serum calcium, partially accomplishing this by increasing bone resorption.

When injected sub-cutaneously, PTH will activate osteoblasts more than osteoclasts. As a consequence, once-daily injection of teriparatide has a net effect of stimulating new bone formation leading to increased bone mineral density.Teriparatide has been shown clinically to improve BMD (Bone Mineral Density) and BMC (Bone Mineral Content) in postmenopausal women and in men. Because of its anabolic capabilities, teriparatide can be used as an alternative to the traditional therapies that are currently available for the treatment of osteoporosis, with scheduled monitoring for adverse effects such as hypercalcemia and urinary calcium excretion.

Teriparatide was approved by the Food & Drug Administration (FDA)on 26 November 2002, for the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture.

Teriparatide is also approved to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.

The product is also used in patients with with a history of osteoporotic fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other available osteoporosis therapies.

Teriparatide is the first, and to date the only, FDA approved agent for the treatment of osteoporosis that stimulates new bone formation. The product is used extensively across the world with excellent results & responses.